|
|
Not Applicable
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
The
|
Emerging growth company |
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
Item 7.01
|
Regulation FD Disclosure.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d)
|
Exhibits.
|
Exhibit
No.
|
Description
|
||
10.1
|
|||
99.1
|
|||
104
|
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
|
DIAMEDICA THERAPEUTICS INC.
|
|||
By:
|
/s/ Scott Kellen
|
||
Scott Kellen
|
|||
Chief Financial Officer and Secretary
|
Exhibit 99.1
DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors
DiaMedica Continues Building Out Board Of Directors With Key Biopharma Industry Leaders
Minneapolis, Minnesota – March 6, 2023 (Business Wire) – DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Tanya Lewis to its board of directors effective March 1, 2023. Ms. Lewis, a recognized leader in the biopharma industry and brings over 25 years of experience in drug development having played a key role in the approval of multiple new drugs.
Ms. Lewis currently serves as the Chief Development Operations Officer at Replimune Group, Inc. where she has oversight for development of an integrated clinical, regulatory and CMC strategy for the successful registration of the company’s compounds. Ms. Lewis joined the executive management team at Replimune in May 2021 after serving on Replimune’s board of directors since November 2020.
Prior to her officer position with Replimune, Tanya was Executive Vice President, Chief Regulatory Strategy and Strategic Operations at Karyopharm Therapeutics Inc., a publicly traded biopharmaceutical company (Nasdaq: KPTI), where she navigated the approval of XPOVIO®. Prior to joining Karyopharm, Ms. Lewis held leadership positions at several companies, including Tesaro and Millennium Pharmaceuticals, where she developed approval strategies and led interactions with U.S. and European regulators for registration trial designs and approvals. Ms. Lewis started her career at Genzyme Corporation in regulatory affairs. Ms. Lewis’s past accomplishments include the successful negotiations for registration trial designs, approval, and/or commercialization of VELCADE®, VARUBI®, INTEGRILIN® and ZEJULA®.
“Tanya is a respected and highly accomplished pharmaceutical industry executive with experience in global drug development and regulatory affairs. We’re very excited to have Tanya join our board of directors at this critical time as we work to resolve the clinical hold on our ReMEDy2 AIS trial.” commented Rich Pilnik, DiaMedica’s Board Chairman.
Ms. Lewis commented. “DiaMedica is at an exciting moment in its evolution and I look forward to working with the board of directors and management team to help the company on its mission to bring DM199 to benefit the millions of stroke patients without a treatment option today.”
Ms. Lewis holds a Bachelor of Science degree in Biology from Northeastern University and a Master of Science degree in Regulatory Affairs and Health Policy from Massachusetts College of Pharmacy and Allied Health Sciences.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease. For more information visit the Company’s website at www.diamedica.com.
Contact:
Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com
Paul Papi
Corporate Communications
Phone: 617-899-5941
ppapi@diamedica.com
Document And Entity Information |
Mar. 01, 2023 |
---|---|
Document Information [Line Items] | |
Entity, Registrant Name | DIAMEDICA THERAPEUTICS INC. |
Document, Type | 8-K |
Document, Period End Date | Mar. 01, 2023 |
Entity, Incorporation, State or Country Code | A1 |
Entity, File Number | 001-36291 |
Entity, Address, Address Line One | 301 Carlson Parkway, Suite 210 |
Entity, Address, City or Town | Minneapolis |
Entity, Address, State or Province | MN |
Entity, Address, Postal Zip Code | 55305 |
City Area Code | 763 |
Local Phone Number | 496-5454 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Voting common shares |
Trading Symbol | DMAC |
Security Exchange Name | NASDAQ |
Entity, Emerging Growth Company | true |
Entity, Ex Transition Period | true |
Amendment Flag | false |
Entity, Central Index Key | 0001401040 |
-8?20$3;8T.P6BP^0"X99K>]9!:G
!<9I3[FK/^"DQNN*#ZL:
M=H_)28667RI46%I.$*M>
MM
S7(!I)Y*NY0<+96
MU,\$MZ5;R/9:?WO$'>NS#=_<:[O)-PZ_.@NU@7C HY&7I]19&AY5HY]<0DO:
M2